Colitis
Conditions
Keywords
ulcerative colitis, Clostidium difficile-associated colitis, Syndecan-1, biomarker
Brief summary
The aim of the study is to evaluate the soluble biomarker syndecan-1 (sSdc1) taken from venous blood of patients with infectious intestinal diseases such as Clostridium difficile-associated colitis, bacterial colitis, Norovirus enteritis and Crohn´s disease or ulcerative colitis. The level of sSdc1 will be compared with disease activity in patients with active inflammation and with disease in remission. Secondary objectives were the assessment of correlation of the above-mentioned factors with the CRP value. Subjects will be volunteers. Blood will be taken as part of the routine clinical work-up after the written agreement blood and sSdc1-level will be assessed using a human-specific sSdc1 ELISA assay. In addition, the subjects are asked to answer a short questionnaire. The study is designed as a prospective, comparative cohort study.
Interventions
None listed
Sponsors
Helios Albert-Schweitzer-Klinik Northeim
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subject with at least 18 years of age * able to give informed consent * healthy volunteer or inflammatory bowel condition (inflammatory bowel disease, infectious colitis)
Exclusion criteria
* not able to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Soluble serum Syndecan-1 in ng/ml | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Patient age | 6 Months |
| Disease activity in Inflammatory bowel disease | 6 Months |
| Underlying disease | 6 months |
| Leucocyte blood count | 6 Months |
| CRP in serum | 6 Months |
| Calprotectin in stool | 6 Months |
Countries
Germany
Contacts
Primary ContactTobias Meister, PD Dr.med.
Outcome results
None listed